Jim Johnston is Executive Director of Research at Amgen with responsibility for Inflammation and Immuno-Oncology. He made a number of key discoveries – including the identification and characterization of JAK3 and work which outlined its importance in autosomal SCID. He was awarded the Most Valuable Scientist award at the BRMP, NIH (1996), the Hajime Award at DNAX, (1999) and the Irish Society of Immunology RDS Public Lecture Award (2010). He founded and was Chief Scientist at Fusion Antibodies Ltd, a company that develops humanized monoclonal antibody therapeutics. At Amgen his group are responsible for the development of nine drugs now in clinical development.